N° CARPETA TERMINO N QUEDAN

1 SCIELO 1

2 SCIELO 2
Bronchopulmonary Dysplasia and
4
Cost

3 SCIELO 3

Bronchopulmonary Dysplasia and

4 SCIELO 0 0
Drug Price
Bronchopulmonary Dysplasia and
5 SCIELO Premature and cost 0 0

bronchopulmonary dysplasia costs

6 SCIELO associated with mechanical 0 0
ventilation
Bronchopulmonary dysplasia and
7 SCIELO 1 1
treatment costs
Bronchopulmonary dysplasia and
8 SCIELO treatment price 0 0
TITULO DUPLICIDAD AÑO SI/NO IDIOMA SOLICITUD
Costos directos de infección respiratoria
0 2018 SI Español NO
baja por VRS en menores de un año

Efectividad del tratamiento con Alveofact®

y Curosurf® en prematuros de 32 semanas
o menos con enfermedad de membrana 2 2016 SI ESPAÑOL NO
hialina en Buga, Valle del Cauca, entre los
años 2006 y 2013

Oxigenoterapia domiciliar prolongada em

crianças e adolescentes: uma análise do
0 2011 SI PORTUGUES NO
uso clínico e de custos de um programa
assistencial

0 0 0 0 0 0

0 0 0 0 0 0

0 0 0 0 0 0
y Curosurf® en prematuros de 32 semanas
o menos con enfermedad de membrana 2 2016 SI ESPAÑOL NO
hialina en Buga, Valle0 del Cauca, entre los 0 0 0 0 0
 CORREO TIPO DE ESTUDIO
juanzepedatoro@gmail.com. Estudio prospectivo longitudinal

lamendozat@gmail.com Estudio de cohorte retrospectivo

Estudio descriptivo retrospectivo y de

andreasm33@gmail.com
cohorte

0 0

0 0

0 0

lamendozat@gmail.com estudio de cohorte retrospectiva

0 0
N° CARPETA TERMINO N QUEDAN

1 LILACS
Bronchopulmonary
3 2
Dysplasia and Cost

2 LILACS

Bronchopulmonary
3 LILACS Dysplasia and Drug
Bronchopulmonary 0 0
4 LILACS Price and
Dysplasia 0 0
dysplasia
Premature andcosts
cost
5 LILACS Bronchopulmonary 0 0
associated with
6 LILACS dysplasia and
Bronchopulmonary 3 1
7 LILACS treatment
dysplasia costs
and 0 0
treatment price
TITULO DUPLICIDAD AÑO SI/NO IDIOMA
Efectividad del tratamiento con Alveofact® y
Curosurf® en prematuros de 32 semanas o
menos con enfermedad de membrana hialina 2 2016 SI Español
en Buga, Valle del Cauca, entre los años 2006 y
2013

Oxigenoterapia domiciliar prolongada em

crianças e adolescentes: uma análise do uso 1 2011 SI Portugues
clínico e de custos de um programa assistencial

0 0 0 0 0
0 0 0 0 0
0
Curosurf® en prematuros de 32 semanas o 0 0 0 0
menos con enfermedad de membrana hialina 2 2016 SI Español
en Buga, Valle del Cauca,
0 entre los años 2006 y 0 0 0 0
SOLICITUD CORREO TIPO DE ESTUDIO

Estudio de cohorte
NO lamendozat@gmail.com
retrospectivo

Estudio descriptivo
NO andreasm33@gmail.com
retrospectivo y de
cohorte

0 0 0
0 0 0
0 0 0
Estudio de cohorte
NO lamendozat@gmail.comretrospectivo
0 0 0
N° CARPETA TERMINO N QUEDAN

1 DOAJ

Bronchopulmona
ry Dysplasia and 6 3
Cost
2 DOAJ

3 DOAJ Bronchopulmona
4 DOAJ ry Dysplasia and 0 0
ry Dysplasia
Drug Priceand
5 DOAJ ryPremature
dysplasia costs 3 1
and
6 DOAJ associated with
Bronchopulmona 0 0
7 DOAJ ry mechanical
dysplasia and
Bronchopulmona 4 0
8 DOAJ treatment
ry dysplasiacosts
and 1 0
treatment price
TITULO DUPLICIDAD AÑO SI/NO

Early treatment versus expectative management of patent

0 2018 SI
ductus arteriosus in preterm infants: a multicentre, randomised,
non-inferiority trial in Europe (BeNeDuctus trial)

Spot protein–creatinine ratio and spot albumin–creatinine

ratio in the assessment of pre-eclampsia: a diagnostic 0 2017 SI
accuracy study with decision-analytic model-based economic
evaluation
The clinical andand
effectiveness acceptability analysisof heated
cost-effectiveness
humidified high-flow nasal cannula compared with usual care for 1 2016 SI
preterm infants: systematic review and economic evaluation
The clinical effectiveness and0cost-effectiveness of heated 0 0 0
humidified high-flow nasal cannula compared with usual care for 1 2016 SI
preterm infants: systematic review
0 and economic evaluation 0 0 0
0 0 0 0
0 0 0 0
IDIOMA SOLICITUD CORREO TIPO DE ESTUDIO

tim.hundscheid@radboud
INGLES NO ensayo aleatorizado
umc.nl

INGLES NO jason.waugh@nuth.nhs.uk metanalisis

revision sistematica -
INGLES NO nigel.fleeman@liverpool.ac.uk
metanalisis
0 0 0 0
revision sistematica-
INGLES NO
metanalisis
0 0 0 0
0 0 0 0
0 0 0 0
N° CARPETA TERMINO
ry dysplasia costs N QUEDAN
1 JSTOR associated with
Bronchopulmona 5 0
2 JSTOR ry mechanical
Dysplasia and 3 0
ry Dysplasia
Drug Priceand
3 JSTOR Bronchopulmona 6 1
Premature and
4 JSTOR ry dysplasia and
Bronchopulmona 15 1
5 JSTOR treatment
ry dysplasiacosts
and 1 1
6 JSTOR treatment price
Bronchopulmona
ry Dysplasia and 10 2
7 JSTOR Cost
 TITULO DUPLICIDAD AÑO SI/NO
0 0 0 0
0 0 0 0
Cost effectiveness of palivizumab in Spain: an
2 2010 SI
analysis using
Cost effectiveness ofobservational
palivizumab indata
Spain: an
2 2010 SI
analysis using observational data
Cost effectiveness of palivizumab in Spain: an
2 2010 SI
analysis using
Cost effectiveness ofobservational
palivizumab indata
Spain: an
the pulmonary hypertension academicdata
research 2 2010 SI
analysis using observational
consortium pediatric advisory committee 1 2013 SI
IDIOMA SOLICITUD CORREO TIPO DE ESTUDIO
0 0 0 0
0 0 0 0
wolfgang.wittenberg@a estudio clinico
INGLES NO
bbott.com
wolfgang.wittenberg@a observacional
estudio clinico
INGLES NO
bbott.com
wolfgang.wittenberg@a observacional
estudio clinico
INGLES NO
bbott.com
wolfgang.wittenberg@a observacional
estudio clinico
INGLES NO
bbott.com observacional
INGLES NO iadatia@ualberta.ca estudio de casos
N° carpeta TERMINO N quedan

1 PUBLMED

2 PUBLMED
bronchopulmonary dysplasia costs
associated with mechanical 9 4
ventilation
3 PUBLMED

4 PUBLMED

Bronchopulmonary Dysplasia and

5 PUBLMED 4 1
Drug Price

6 PUBLMED
7 PUBLMED
8 PUBLMED Bronchopulmonary dysplasia and 59 6
9 PUBLMED treatment costs
10 PUBLMED
11 PUBLMED

12 PUBLMED

13 PUBLMED Bronchopulmonary Dysplasia and

89 6
14 PUBLMED Premature and cost
15 PUBLMED
16 PUBLMED
17 PUBLMED
18 PUBLMED
Bronchopulmonary dysplasia and
treatment price 16 2
19 PUBLMED

20 PUBLMED

21 PUBLMED Bronchopulmonary Dysplasia and

163 4
Cost

22 PUBLMED

23 PUBLMED
TITULO duplicidad año si/no

Predictors of length of stay for initial hospitalization in

1 2018 NO
infants with bronchopulmonary dysplasia

The economic impact of prematurity and

5 2017 NO
bronchopulmonary dysplasia.

The potential of non-invasive ventilation to decrease BPD 0 2013 NO

Economic evaluation of inhaled nitric oxide in preterm

4 2009 NO
infants undergoing mechanical ventilation.

Cost effectiveness of palivizumab for RSV prevention in

2 2009 SI
high-risk children in the Netherlands
Direct costs of low respiratory infection due to RSV in
0 2018 SI
children
The economic underofone
impact year
prematurity and
3 2017 NO
bronchopulmonary dysplasia.
Influence of own mother's milk on bronchopulmonary
0 2017 SI
respiratory support dysplasia and costs.
in newborn infants: a difference-in-
1 2014 SI
difference analysis using data from the Norwegian patient
Cost of morbidities in very low birth weight infants. 0 2013 SI
Economic evaluation of inhaled nitric oxide in preterm
5 2009 NO
infants undergoing mechanical ventilation.
Long-term effects of the intratracheal administration of
corticosteroids for the prevention of bronchopulmonary 0 2019 NO
dysplasia: A meta-analysis.
Erythropoietin treatment is associated with a reduction in
moderate to severe bronchopulmonary dysplasia in 0 2019 NO
Bronchopulmonary
preterm infants. Dysplasia: Anretrospective
A regional Update on Experimental
study 0 2019 SI
Therapeutics.
Pulmonary Surfactant for Preventing Bronchopulmonary
PerinatalPreterm
factors Infants
associated 0 2019 NO
Dysplasia in withwith bubbly/cystic
Neonatal Respiratory
appearance in bronchopulmonary dysplasia:
Relationship between severe bronchopulmonary a 0 2019 NO
nationwide, population-based cohort study in
dysplasia and severe retinopathy of prematurity Japan. 0 2019 NO
Economic evaluation of inhaled nitric oxide in preterm
in premature newborns.
infants undergoing mechanical ventilation. 5 2009 NO
Cost effectiveness of palivizumab for RSV prevention in
2 2009 SI
high-risk children in the Netherlands

Morbidity and cost burden of prenatal myelomeningocele

0 2019 SI
repair

Direct costs of low respiratory infection due to RSV in

0 2018 SI
children under one year.
Economic benefits and costs of human milk feedings: A
strategy to reduce the risk of prematurity-related 1 2014 SI
morbidities in very-low-birth-weight infants
Cost of morbidities in very low birth weig 0 2013 SI
IDIOMA SOLICITUD CORREO TIPO DE ESTUDIO

INGLES SI mcollac1@jhmi.edu estudio restropectivo

INGLES SI fuente@salud.madrid.org estudio de casos y control

INGLES SI vineet.bhandari@yale.edu estudio de casos y control

INGLES SI jzupanci@bidmc.harvard.edu estudio clinico aleatorizado

INGLES NO nuijten@bmg.eur.nl estudio de casos

INGLES NO Estudio longitudinal prospectivo

INGLES SI fuente@salud.madrid.org estudio de casos y control
INGLES NO estudio prospectivo
.Kann@ahus.no
INGLES NO metanalisis
a.l.solevag@medisin.uio.no
INGLES NO tricia_j_johnson@rush.edu estudio de cohorte retrospectivo
INGLES SI jzupanci@bidmc.harvard.edu estudio clinico aleatorizado

INGLES NO cyyang996@qq.com META-ANALISIS

INGLES NO ESTUDIO RETROSPECTIVO

INGLES NO ESTUDIO EXPERIMENTAL
INGLES NO yanbaixh@hust.edu.cn. META-ANALISIS
INGLES NO ESTUDIO COHORTE
INGLES NO  jasleen.singh@ucdenver.edu. ESTUDIO COHORTE
INGLES SI jzupanci@bidmc.harvard.edu estudio clinico aleatorizado

INGLES NO nuijten@bmg.eur.nl estudio de casos

INGLES NO estudio de cohorte retrospectivo

INGLES NO Estudio longitudinal prospectivo

INGLES NO tricia_j_johnson@rush.edu revision sistematica

INGLES NO tricia_j_johnson@rush.edu revision sistematica

N° CARPETA TERMINO
Bronchopulmonary N QUEDAN
1 SCOPUS Dysplasia and Drug 3 1
2 SCOPUS Price
bronchopulmonary
dysplasia costs
20 2
3 SCOPUS associated with
mechanical ventilation
4 SCOPUS Bronchopulmonary
5 SCOPUS dysplasia and 4 3
6 SCOPUS treatment price
7 SCOPUS
8 SCOPUS
9 SCOPUS
10 SCOPUS Bronchopulmonary
Dysplasia and 77 8
11 SCOPUS Premature and cost
12 SCOPUS
13 SCOPUS
14 SCOPUS
15 SCOPUS

16 SCOPUS

17 SCOPUS

Bronchopulmonary
18 SCOPUS dysplasia and 68 7
treatment costs

19 SCOPUS

20 SCOPUS

21 SCOPUS

22 SCOPUS
23 SCOPUS

24 SCOPUS

Bronchopulmonary
68 7
25 SCOPUS Dysplasia and Cost

26 SCOPUS

27 SCOPUS

28 SCOPUS
TITULO DUPLICIDAD AÑO
Cost effectiveness of palivizumab for RSV prevention in
3 2009
Predictorshigh-risk children
of length of stayinfor
the Netherlands
initial hospitalization in
1 2018
infants with bronchopulmonary dysplasia
Economic evaluation of inhaled nitric oxide in preterm
4 2009
infants undergoing mechanical ventilation.
Should we still use Vitamin A to prevent
0 2016
bronchopulmonary
Cost effectiveness of palivizumabdysplasia?
for RSV prevention in
3 2009
high-risk children in the Netherlands
Economic evaluation of inhaled nitric oxide in preterm
5 2009
infants
Trends undergoing and
in epidemiology mechanical
outcomes ventilation.
of respiratory
Enteraldistress
Nutrition Tolerance 0 2019
syndrome in and REspiratory
the United StatesSupport
(ENTARES) Study in preterm infants: Study protocol for a 0 2019
The economic impact
randomized of prematurity
controlled trial and
unit: A team work to promotedysplasia.
bronchopulmonary the rational use of 4 2017
antibiotics [Evaluación del consumo de antimicrobianos ¨0 2017
enInfluence
una unidadof own mother's milkUn
de neonatología: ontrabajo
bronchopulmonary
en equipo para 0 2017
respiratory support dysplasia and infants:
in newborn costs a difference-in-
Economicanalysis
difference benefitsusing
and costs of human
data from milk feedings:
the Norwegian A
patient 1 2014
strategy to reduce the risk of prematurity-related 1 2014
Costmorbidities in very-low-birth-weight
of morbidities in very low birth weight infants
infants 0 2013
Retrospective analysis on the treatment of 231 cases of
0 2016
very low or extremely low birth weight infants
The clinical effectiveness and cost-effectiveness of heated
humidified high-flow nasal cannula compared with usual
0 2016
care for preterm infants: Systematic review and economic
evaluation

Assessing the Response to Inhaled Albuterol by

Monitoring Patient Effort-Related Trends with a Servo-I
Ventilator in Neurally Adjusted Ventilatory Assist Mode: A 0 2015
Case Presentation

Economic and health consequences of non-invasive

respiratory support in newborn infants: A difference-in-
2 2014
difference analysis using data from the Norwegian patient
registry

Social, economic, and health impact of the respiratory

1 2014
syncytial virus: A systematic search

The potential of non-invasive ventilation to decrease BPD 0 2013

Cost-effectiveness of palivizumab for respiratory syncytial

virus infection in high-risk children, based on long-term 1 2012
epidemiologic data from Austria

Retrospective analysis on the treatment of 231 cases of

0 2016
very low or extremely low birth weight infants
The clinical effectiveness and cost-effectiveness of heated
humidified high-flow nasal cannula compared with usual
0 2016
care for preterm infants: Systematic review and economic
evaluation

Social, economic, and health impact of the respiratory

1 2014
syncytial virus: A systematic search

Economic and health consequences of non-invasive

respiratory support in newborn infants: A difference-in-
1 2014
difference analysis using data from the Norwegian patient
registry

Cost-effectiveness of palivizumab for respiratory syncytial

virus infection in high-risk children, based on long-term 1 2012
epidemiologic data from Austria

Cost effectiveness of palivizumab for RSV prevention in

2 2009
high-risk children in the Netherlands

Economic evaluation of inhaled nitric oxide in preterm 4 2009

infants undergoing mechanical ventilation.
SI/NO IDIOMA SOLICITUD CORREO TIPO DE ESTUDIO
SI INGLES NO nuijten@bmg.eur.nl estudio de casos
NO INGLES SI mcollac1@jhmi.edu estudio restropectivo

jzupanci@bidmc.harvard.e estudio clinico

NO INGLES SI
du aleatorizado

SI INGLES NO xanthic@bcm.edu revision sistematica

SI INGLES NO nuijten@bmg.eur.nl estudio de casos
jzupanci@bidmc.harvard.e estudio clinico
NO INGLES SI
du
sratogi@maimonidesmed. aleatorizado
estudio transversal
SI INGLES NO estudio controlado
org retrospectivo
SI INGLES NO elena.maggiora@gmail.com multicéntrico,
estudio de casos y
aleatorizado
NO INGLES SI fuente@salud.madrid.org control
observacional,
SI INGLES NO soteroneo@gmail.com prospectivo,
estudio de cohorte
SI INGLES NO Aloka_Patel@Rush.edu
prospectivo
SI INGLES NO a.l.solevag@medisin.uio.n metanalisis
tricia_j_johnson@rush.ed
SI INGLES NO u revision sistematica
SI INGLES NO tricia_j_johnson@rush.edu estudio sistematico
SI INGLES NO estudio restropectivo

SI INGLES NO nigel.fleeman@liverpool.ac.uk
estudio sistematico

SI INGLES NO tsnow@wfubmc.edu estudio de casos

SI INGLES NO Inger.Cathrine.Kann@ahus.no
estudio experimental

SI INGLES NO plazaro@taiss.com revision sistematica

SI INGLES NO vineet.bhandari@yale.edu revision sistematica

SI INGLES NO Bernhard.resch@medunigraz.at
revision sistematica

SI INGLES NO estudio restropectivo

SI INGLES NO nigel.fleeman@liverpool.ac.uk
revision sistematica

SI INGLES NO plazaro@taiss.com revision sistematica

SI INGLES NO Inger.Cathrine.Kann@ahus.no
estudio experimental

SI INGLES NO Bernhard.resch@medunigraz.at
revision sistematica

SI INGLES NO nuijten@bmg.eur.nl estudio de casos

NO INGLES SI jzupanci@bidmc.harvard.e estudio clinico

du aleatorizado
N° CARPETA TERMINO N QUEDAN
dysplasia costs
1 OXFORD Bronchopulmonary 14 1
associated with
2 OXFORD Dysplasia and Drug 28 2
3 OXFORD Price
Bronchopulmonary
dysplasia and 38 3
4 OXFORD treatment price
5 OXFORD Bronchopulmonary
Dysplasia and 131 4
6 OXFORD Premature and cost
7 OXFORD Bronchopulmonary
dysplasia and 142 5
8 OXFORD treatment costs
Bronchopulmonary
9 OXFORD 167 6
Dysplasia and Cost
TITULO DUPLICIDAD AÑO SI/NO
0 0 0 0
Feedings: A Strategy to Reduce the Risk of
5 2014 SI
Prematurity-Related Morbidities
Feedings: A Strategy to Reducein Very-Low-Birth-
the Risk of
5 2014 SI
Prematurity-Related Morbidities in Very-Low-Birth-
The Economics of Strategies to Reduce Respiratory
2 2013 SI
Syncytial Virus Hospitalizations in Alaska
Feedings: A Strategy to Reduce the Risk of
5 2014 SI
Prematurity-Related Morbidities
The Economics of Strategies in Very-Low-Birth-
to Reduce Respiratory
2 2013 SI
Syncytial Virus Hospitalizations in Alaska
Feedings: A Strategy to Reduce the Risk of
5 2014 SI
Prematurity-Related Morbidities
The Economics of Strategies in Very-Low-Birth-
to Reduce Respiratory
2 2013 SI
Syncytial Virus Hospitalizations in Alaska
Feedings: A Strategy to Reduce the Risk of
5 2014 SI
Prematurity-Related Morbidities in Very-Low-Birth-
IDIOMA SOLICITUD CORREO TIPO DE ESTUDIO
0 0 0 0
INGLES NO metanalisis
INGLES NO revision sistematica
INGLES NO estudio restrospectivo
INGLES NO revision sistematica
INGLES NO estudio restrospectivo
INGLES NO revision sistematica
INGLES NO estudio restrospectivo
INGLES NO revision sistematica
N° CARPETA TERMINO N QUEDAN
dysplasia costs
1 EBSCO Bronchopulmonary 1 0
associated with
2 EBSCO Dysplasia and Drug 2 1
3 EBSCO Price
Bronchopulmonary
4 EBSCO dysplasia and 33 3
5 EBSCO treatment costs
6 EBSCO
7 EBSCO
8 EBSCO
9 EBSCO
10 EBSCO Bronchopulmonary
11 EBSCO Dysplasia and 88 11
12 EBSCO Premature and cost
13 EBSCO
14 EBSCO
15 EBSCO
16 EBSCO
Bronchopulmonary
17 EBSCO dysplasia and 0 0
treatment price
18 EBSCO
19 EBSCO Bronchopulmonary
176 4
20 EBSCO Dysplasia and Cost
21 EBSCO
 TITULO DUPLICIDAD AÑO SI/NO IDIOMA
Economic evaluation 0of inhaled nitric oxide 0 0 0 0
in preterm infants undergoing mechanical 4 2009 NO INGLES
The economic impact of prematurity and
ventilation.
Lower Rate of Reintubationdysplasia
Observed With 3 2017 SI INGLES
bronchopulmonary
SURFAXIN®
Economic Treatment
evaluation May Reduce
of inhaled nitric oxide 0 2012 SI INGLES
Hospital Costs Associated with
in preterm infants undergoing mechanical 5 2009 SI INGLES
The economic impact of prematurity and
ventilation. 3 2017 SI INGLES
bronchopulmonary
Influence of own mother'sdysplasia
milk on
Respiratory morbidity, healthcare 2 2016 SI INGLES
bronchopulmonary dysplasia and costs.
utilisation and cost of care at school age 2 2011 SI INGLES
Milkrelated
Feedings: A Strategy
to home oxygen to Reduce
status. the
Economic evaluation of recombinant 5 2014 SI INGLES
Risk of Prematurity-Related Morbidities in
human copper zinc superoxide dismutase
Economic evaluation of inhaled nitric oxide 0 2009 SI INGLES
administered
inClinical
pretermand at birth
infants to premature
undergoing infants. 5 2009 SI INGLES
Economic Effectsmechanical
of iNO in
ventilation.
Premature Newborns With Respiratory 0 2009 SI INGLES
respiratory syncytial virus
Failure at infection in high-
1 Year.
Costrisk
effectiveness of palivizumab for RSV 2 2012 SI INGLES
children, based on long-term
prevention in high-risk children in the 3 2009 SI INGLES
invasive respiratory support in newborn
Netherlands 2 2014 SI INGLES
infants: a difference-in-difference
respiratory syncytial virus infectionanalysis
in high-
2 2012 SI INGLES
risk children, based on long-term

0 0 0 0 0

The economic impact of prematurity and

0 2017 SI INGLES
bronchopulmonary
Influence dysplasia.
of own mother's milk on
Respiratory morbidity,
bronchopulmonary healthcare
dysplasia and costs. 2 2016 SI INGLES
utilisation and cost of care at school age 2 2011 SI INGLES
Milkrelated
Feedings: A Strategy
to home to Reduce
oxygen status. the 5 2014 SI INGLES
Risk of Prematurity-Related Morbidities in
SOLICITUD CORREO TIPO DE ESTUDIO
0 0 0
SI jzupanci@bidmc.harvard.edu estudio clinico aleatorizado
NO m.alvarez.fuente@salud.madrid.org. estudio de casos
NO estudio de casos
NO jzupanci@bidmc.harvard.edu estudio aleatorizado
NO m.alvarez.fuente@salud.madrid.org. estudio de casos
estudio de cohorte
NO
prospectivo
NO anne.greenough@kcl.ac.uk estudio de casos
NO revision sistematica
NO estudio controlado aleatorio
NO jzupanci@bidmc.harvard.edu estudio aleatorizado
NO estudio aleatorizado
NO Bernhard.resch@medunigraz.at revision sistematica
NO nuijten@bmg.eur.nl estudio de casos
NO Inger.Cathrine.Kann@ahus.no estudio experimental
NO Bernhard.resch@medunigraz.at revision sistematica

0 0 0

m.alvarez.fuente@salud.madrid.org. estudio de casos

estudio de cohorte
NO prospectivo
NO anne.greenough@kcl.ac.uk estudio de casos
NO revision sistematica
N° CARPETA TERMINO N QUEDAN
bronchopulmonary dysplasia costs
1 SCIENCE DIRECT associated with mechanical 330 1
ventilation

2 SCIENCE DIRECT
Bronchopulmonary Dysplasia and
121 2
Drug Price
3 SCIENCE DIRECT

Bronchopulmonary dysplasia and

4 SCIENCE DIRECT treatment costs
Bronchopulmonary Dysplasia and 631 1
5 SCIENCE DIRECT Premature and cost 955 1
6 SCIENCE DIRECT
Bronchopulmonary dysplasia and
7 SCIENCE DIRECT 154 3
treatment price
8 SCIENCE DIRECT

9 SCIENCE DIRECT
Bronchopulmonary Dysplasia and
10 SCIENCE DIRECT 1.177 4
Cost
11 SCIENCE DIRECT
12 SCIENCE DIRECT
 DUPLICID
TITULO AD AÑO
Cost-Effectiveness Analysis of Nasal Continuous Positive Airway Pressure
Versus Nasal High Flow Therapy as Primary Support for Infants Born
Preterm
1 2017

Cost of Morbidities in Very Low Birth Weight Infants 0 2013

PIH29 - Cost-Effectiveness Of Prophylaxis Of Respiratory Syncytial Virus

Infection (RSV) With Palivizumab In Preterm Infants In Colombia 0 2013
The direct and indirect influence of own mother's milk
on bronchopulmonary dysplasia and costs. 0 2016
The economic impact of prematurity and bronchopulmonary dysplasia. 4 2017
Cost of Morbidities
PIH29 - Cost-Effectiveness Of in Very Low Birth
Prophylaxis Weight Infants
Of Respiratory Syncytial Virus 0 2013
Infection (RSV) With Palivizumab In Preterm Infants In Colombia
Versus Nasal High Flow Therapy as Primary Support for Infants Born 0 2013
Preterm 1 2018
Cost-effectiveness of palivizumab against respiratory syncytial viral
infection in high-risk children in Austria 0 2008
Versus Nasal High Flow Therapy as Primary Support for Infants Born
Preterm 0 2017
Cost of Morbidities in Very Low Birth
PIH29 - Cost-Effectiveness Of Prophylaxis Weight Infants
Of Respiratory Syncytial Virus 0 2013
Infection (RSV) With Palivizumab In Preterm Infants In Colombia 0 2013
 SOLICITU
SI/NO IDIOMA D CORREO TIPO DE ESTUDIO

estudio de control
SI INGLES NO kim.dalziel@unimelb.edu.au aleatorio multicéntrico

estudio de cohorte y
SI INGLES NO control

estudio de casos y
SI INGLES NO control
SI INGLES NO alvarez.fuente@salud.madr estudio de casos y
SI INGLES NO id.org. estudiocontrol
de cohorte y
SI INGLES NO control
estudio de casos y
SI INGLES NO control
estudio de casos y
SI INGLES NO control
estudio de casos y
SI INGLES NO control
estudio de casos y
SI INGLES NO estudiocontrol
de cohorte y
SI INGLES NO control
estudio de casos y
SI INGLES NO control
N° CARPETA TERMINO N QUEDAN
1 PROSQUEST
2 PROSQUEST bronchopulmonary
dysplasia costs associated
3 PROSQUEST 704 5
with mechanical
4 PROSQUEST ventilation
5 PROSQUEST
6 PROSQUEST Bronchopulmonary
433 2
7 PROSQUEST Dysplasia and Drug Price
Bronchopulmonary
9 PROSQUEST dysplasia and treatment 2,242 1
10 PROSQUEST costs
Bronchopulmonary 2,381 2
11 PROSQUEST Dysplasia and Cost
12 PROSQUEST Bronchopulmonary
13 PROSQUEST Dysplasia and Premature 1,747 3
14 PROSQUEST and cost
Bronchopulmonary
15 PROSQUEST dysplasia and treatment 702 1
price
 TITULO DUPLICIDAD AÑO SI/NO IDIOMA
The economic impact of prematurity and
3 2017 SI INGLES
Predictors of bronchopulmonary dysplasia
length of stay for initial hospitalization
1 2018 SI INGLES
inrespiratory
infants with bronchopulmonary dysplasia
support in newborn infants: a
Improved clinical and economic 0 2014 SI INGLES
difference-in-difference analysis outcomes
using datain severe
from the
bronchiolitis with pre-emptive nCPAP ventilatory 0 2013 SI INGLES
Cost comparison of mechanically
strategy ventilated patients 0 2015 SI INGLES
across
Should we still usethevitamin
age span
A to prevent
0 2016 SI INGLES
Influence of own mother's milk ?on
bronchopulmonary dysplasia
0 2016 SI INGLES
The economic impactdysplasia
bronchopulmonary and costs
of prematurity and
3 2017 SI INGLES
bronchopulmonary dysplasia
The economic impact of prematurity and
3 2017 SI INGLES
bronchopulmonary
Influence of own mother'sdysplasia
milk on
0 2017 SI INGLES
bronchopulmonary dysplasia
The economic impact of prematurity and costs
and
3 2017 SI INGLES
bronchopulmonary dysplasia
Influence of own mother's milk on
0 2017 SI INGLES
bronchopulmonary
The direct dysplasia
and indirect influence ofand
owncosts
mother's
0 2017 SI INGLES
milk on bronchopulmonary dysplasia
The economic impact of prematurity and and costs
3 2017 SI INGLES
bronchopulmonary dysplasia
SOLICITUD CORREO TIPO DE ESTUDIO
estudio de casos
NO fuente@salud.madrid.org
yestudio
control
NO mcollac1@jhmi.edu
restropectivo
NO metanalisis
Estudio de
NO sandrine.essouri@bct.aphp.fr cohorte
estudio de casos
retrospectivo
NO
y control
NO metanalisis
estudio de
NO cohorte
estudio de casos
prospectivo
NO fuente@salud.madrid.org
y control
estudio de casos
NO fuente@salud.madrid.org estudio de
y control
NO cohorte
estudio de casos
prospectivo
NO fuente@salud.madrid.org estudio de
y control
NO cohorte
prospectivo
NO
observacional de
estudio de casos
NO fuente@salud.madrid.org
y control